Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy

T cells expressing anti-CD19 chimeric antigen receptors (CARs) can induce complete remissions (CRs) of diffuse large B cell lymphoma (DLBCL). The long-term durability of these remissions is unknown. We administered anti-CD19 CAR T cells preceded by cyclophosphamide and fludarabine conditioning chemo...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Mol Ther
Autori principali: Kochenderfer, James N., Somerville, Robert P.T., Lu, Tangying, Yang, James C., Sherry, Richard M., Feldman, Steven A., McIntyre, Lori, Bot, Adrian, Rossi, John, Lam, Norris, Rosenberg, Steven A.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Gene & Cell Therapy 2017
Soggetti:
Original Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5628864/
https://ncbi.nlm.nih.gov/pubmed/28803861
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ymthe.2017.07.004
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi